Reduced intensity allogeneic HSCT to hypomethylating therapy or best supportive care in older patients with advanced MDS

Emerging treatments for relapsed/refractory Hodgkin’s lymphoma in China

The Burkitt lymphoma international prognostic index

Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with AML

Long-term follow-up of low-intensity chemotherapy with combination therapy for r/r Ph- acute lymphoblastic leukaemia patients

Real-world evidence of the use of carfilzomib among multiple myeloma patients across 10 European countries and Israel

Real-world evidence of the use of carfilzomib to refractory to lenalidomide patients

A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumumab and bortezomib

PRWCC: Disease burden impacts outcomes in paediatric and young adult B-Cell ALL after commercial tisagenlecleucel

Researchers trace the origin of blood cancer to early childhood, decades before diagnosis

ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma

Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomised Forte trial

ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with phosphoethanolamine

FORTE: Impact of imaging FDG-PET/CT minimal residual disease assessment on multiple myeloma patients

Clinical activity and safety of cevostamab in relapsed/refractory multiple myeloma

ASCEMBL: Asciminib for hard-to-treat chronic myeloid leukaemia

ASCENT: A phase II trial of induction, consolidation and maintenance in subjects with high risk smouldering MM

Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia: results of the ITCC-059 study

MURANO: Sustained disease survival in CLL following venetoclax plus rituximab

Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CLL

Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma

ASH 2020: Targeted therapies in r/r multiple myeloma

Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment

Decitabine plus ipilimumab in r/r MDS/AML in the post-BMT or transplant naïve settings

Treating acute leukaemias of ambiguous lineage

Continuous therapy in multiple myeloma; updates from MM4 and MM6 including China perspective

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma

Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin lymphoma real world evidence data

Five year update of ECHELON-1 for classical Hodgkin lymphoma

Off-the-shelf multi-virus specific T cells following haematopoietic stem cell transplantation

Blinatumomab and oral TKIs for the treatment of Ph ALL

D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph ALL

Real world management of multiple myeloma patients

Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results

Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients

FORTE trial: Impact of minimal residual disease on multiple myeloma patients

Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study

ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma

Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma

Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in newly diagnosed or R/R AML

Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell ALL

Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL

Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated on the Interfant-06 protocol

Predictive factors for overall survival in chronic myeloid leukaemia patients: an analysis by the Gimema CML Italian study

Cranial radiation mostly eliminated in children with T-ALL and bortezomib potentially improves survival in children with T-LL

Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukaemia